Trend Analysis of Sexually Transmitted Infection Treatments in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The revision of the 2023 Guidelines for the Treatment of Sexually Transmitted Infections (STIs) has been released. Hence, it is necessary to analyze the current status of STI treatments in Korea. Materials and Methods: A questionnaire was distributed to urologists and gynecologists from December 2022 to January 2023 through an online survey program. Three hundred and forty-one urologists and 302 gynecologists responded to the questionnaire. Results: For Neisseria gonorrhea treatment, ceftriaxone 500 mg and 100 mg of doxycycline twice daily for seven days were most preferred by urologists (22.58%). The treatment most preferred by gynecologists (15.23%) was 500 mg of ceftriaxone and 1 g of azithromycin in a single dose. Both urologists and gynecologists generally treat Chlamydia trachomatis according to the treatment guidelines. For treating Mycoplasma genitalium, 29.03% of urologists preferred administering azithromycin at 500 mg once daily, followed by 250 mg for four days. In contrast, 33.11% of gynecologists preferred doxycycline 100 mg twice daily for seven days. Conclusions: Most urologists and gynecologists followed the treatments recommended in the 2nd edition of the STI treatment guidelines, revised in 2016. As many treatment regimens have changed because of the recent increase in antibiotic-resistant STIs, there is a need to encourage them to follow the new treatment guidelines.
Abstract
Purpose: The revision of the 2023 Guidelines for the Treatment of Sexually Transmitted Infections (STIs) has been released. Hence, it is necessary to analyze the current status of STI treatments in Korea. Materials and Methods: A questionnaire was distributed to urologists and gynecologists from December 2022 to January 2023 through an online survey program. Three hundred and forty-one urologists and 302 gynecologists responded to the questionnaire. Results: For Neisseria gonorrhea treatment, ceftriaxone 500 mg and 100 mg of doxycycline twice daily for seven days were most preferred by urologists (22.58%). The treatment most preferred by gynecologists (15.23%) was 500 mg of ceftriaxone and 1 g of azithromycin in a single dose. Both urologists and gynecologists generally treat Chlamydia trachomatis according to the treatment guidelines. For treating Mycoplasma genitalium, 29.03% of urologists preferred administering azithromycin at 500 mg once daily, followed by 250 mg for four days. In contrast, 33.11% of gynecologists preferred doxycycline 100 mg twice daily for seven days. Conclusions: Most urologists and gynecologists followed the treatments recommended in the 2nd edition of the STI treatment guidelines, revised in 2016. As many treatment regimens have changed because of the recent increase in antibiotic-resistant STIs, there is a need to encourage them to follow the new treatment guidelines.
참고문헌 (21)
- Korea Centers for Disease Control and Prevention (KCDC), "Korean sexually transmitted infection guidelines" (2016), KCDC
- Korea Disease Control and Prevention Agency (KDCA), "Korean sexually transmitted infection guidelines" (2023), KCDA
- Cole MJ, "Overall low extended-spectrum cephalosporin resistance but high azithromycin resistance in Neisseria gonorrhoeae in 24European Countries, 2015", BMC Infect Dis, 17, pp.617~ (2017)
- Day MJ, "Significant increase in azithromycin "resistance" and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019", BMC Infect Dis, 22, pp.524~ (2022)
- Fifer H, "Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England : an observational study", Lancet Infect Dis, 18, pp.573~581 (2018)
- Wi T, "Antimicrobial resistance in Neisseria gonorrhoeae : global surveillance and a call for international collaborative action", PLoS Med, 14, pp.e1002344~ (2017)
- Yasuda M, "Remarkable increase of Neisseria gonorrhoeae with decreased susceptibility of azithromycin and increase in the failure of azithromycin therapy in male gonococcal urethritis in Sendai in 2015", J Infect Chemother, 22, pp.841~843 (2016)
- Ross JDC, "Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial", Lancet, 393, pp.2511~2520 (2019)
- Chisholm SA, "Cephalosporin MIC creep among gonococci : time for a pharmacodynamic rethink?", J Antimicrob Chemother, 65, pp.2141~2148 (2010)
- Lee H, "Emergence and spread of cephalosporin-resistant Neisseria gonorrhoeae with Mosaic penA alleles, South Korea, 2012-2017", Emerg Infect Dis, 25, pp.416~424 (2019)
- Lahra MM, "Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain", Emerg Infect Dis, 24, pp.735~740 (2018)
- Eyre DW, "Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018", Euro Surveill, 23, pp.1800323~ (2018)
- Radovanovic M, "Current susceptibility surveillance and distribution of antimicrobial resistance in N. gonorrheae within WHO regions", Pathogens, 11, pp.1230~ (2022)
- Yang HJ, "2023Korean Association of Urogenital Tract Infection and Inflammation guidelines for gonococcal infection", Investig Clin Urol, 65, pp.1~8 (2024)
- Gaydos C, "Mycoplasma genitalium compared to chlamydia, gonorrhoea and trichomonas as an aetiological agent of urethritis in men attending STD clinics", Sex Transm Infect, 85, pp.438~440 (2009)
- Svenstrup HF, "A cross-sectional study of Mycoplasma genitalium infection and correlates in women undergoing population-based screening or clinic-based testing for Chlamydia infection in London", BMJ Open, 4, pp.e003947~ (2014)
- Getman D, "Mycoplasma genitalium prevalence, coinfection, and macrolide antibiotic resistance frequency in a multicenter clinical study cohort in the United States", J Clin Microbiol, 54, pp.2278~2283 (2016)
- Durukan D, "Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5 g azithromycin for the treatment of Mycoplasma genitalium infection:efficacy and tolerability", Clin Infect Dis, 71, pp.1461~1468 (2020)
- Li Y, "Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection", Int J STD AIDS, 28, pp.1106~1114 (2017)
- Read TRH, "Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections : a prospective evaluation", Clin Infect Dis, 68, pp.554~560 (2019)
- Horner P, "Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women?-a position statement from the European STI Guidelines Editorial Board", J Eur Acad Dermatol Venereol, 32, pp.1845~1851 (2018)